www.uncoverlpa.com Open in urlscan Pro
2606:4700:4400::6812:2a28  Public Scan

Form analysis
0 forms found in the DOM

Text Content

Skip to main content
 * Home
 * What is Lp(a)?
 * Screening
 * Management
 * Resources
 * Get Lp(a) Updates

8/23     283430
For PublicHCPs
This site is for US Health Care Professionals Only
ELEVATED LP(A)
MAY BE HIDING
IN YOUR PATIENT'S
LIPID PROFILE

~ 1 in 5 people may inherit elevated Lp(a),
a lifelong cardiovascular risk factor1-3

Get Lp(a) Updates


WHAT MAKES ELEVATED LP(A) UNIQUE MAY ALSO MAKE IT A THREAT TO YOUR PATIENTS

Watch this video to see what makes it so different from other cardiovascular
risk factors.

Read the Transcript >


INTRODUCTION TO LP(A)

 * Lp(a) is a unique form of lipoprotein that is proatherogenic,
   proinflammatory, and prothrombotic at elevated levels4,5
    

 * Large-scale genetic studies have confirmed that elevated Lp(a) is an
   independent and causal cardiovascular risk factor2,6-8
    

 * Elevated Lp(a) contributes to a consistent and lifelong risk of heart attack
   and stroke2


UNCOVER MORE ABOUT ELEVATED LP(A) 

Elevated Lp(a) is one of the strongest single genetic risk factors for coronary
artery disease.8

View the Data

Screening for elevated Lp(a) requires only a simple blood test that can be added
to any routine blood work.9

Learn More

Knowing a patient's Lp(a) levels can help inform a lifetime of cardiovascular
care.2,3,10-12

See How

References: 1. Tsimikas S, Fazio S, Ferdinand KC, et al. NHLBI Working Group
recommendations to reduce lipoprotein(a)-mediated risk of cardiovascular disease
and aortic stenosis. J Am Coll Cardiol. 2018;71(2):177-192. 2. Kronenberg F,
Mora S, Stroes ESG, et al. Lipoprotein(a) in atherosclerotic cardiovascular
disease and aortic stenosis: a European Atherosclerosis Society consensus
statement. Eur Heart J. 2022;14:43(39):3925-3946. 3. Wilson DP, Jacobson TA,
Jones PH, et al. Use of lipoprotein(a) in clinical practice: A biomarker whose
time has come. A scientific statement from the National Lipid Association. J
Clin Lipidol. 2019;13(3):374-392. 4. Reyes-Soffer G, Ginsberg HN, Berglund L, et
al; American Heart Association Council on Arteriosclerosis, Thrombosis and
Vascular Biology; Council on Cardiovascular Radiology and Intervention; and
Council on Peripheral Vascular Disease. Lipoprotein(a): a genetically
determined, causal, and prevalent risk factor for atherosclerotic cardiovascular
disease: a scientific statement from the American Heart Association.
Arterioscler Thromb Vasc Biol. 2022;42(1):e48-e60. 5. Jawi MM, Frohlich J, Chan
SY. Lipoprotein(a) the insurgent: a new insight into the structure, function,
metabolism, pathogenicity, and medications affecting lipoprotein(a) molecule. J
Lipids. 2020;2020:3491764. doi: 10.1155/2020/3491764 6. Enas EA, Varkey B,
Dharmarajan TS, Pare G, Bahl VK. Lipoprotein(a): An independent, genetic, and
causal factor for cardiovascular disease and acute myocardial infarction. Indian
Heart J. 2019;71(2):99-112. 7. Nordestgaard BG, Chapman MJ, Ray K, et al;
European Atherosclerosis Society Consensus Panel. Lipoprotein(a) as a
cardiovascular risk factor: current status. Eur Heart J.
2010;31(23):2844-2853. 8. Tsimikas S. A test in context: Lipoprotein(a):
Diagnosis, prognosis, controversies, and emerging therapies. J Am Coll Cardiol.
2017;69(6):692-711. 9. Farzam K, Senthilkumaran S. Lipoprotein A. In: StatPearls
[Internet]. Treasure Island (FL): StatPearls Publishing; 2022. Updated September
2, 2022. Accessed August 22, 2023.
https://www.statpearls.com/ArticleLibrary/viewarticle/130795 10. Virani SS,
Koschinsky ML, Maher L, et al. Global think tank on the clinical considerations
and management of lipoprotein(a): The top questions and answers regarding what
clinicians need to know. Prog Cardiovasc Dis. 2022;73:32-40. 11. Willeit P,
Kiechl S, Kronenberg F, et al. Discrimination and net reclassification of
cardiovascular risk with lipoprotein(a): prospective 15-year outcomes in the
Bruneck Study. J Am Coll Cardiol. 2014;64(9):851-860. 12. Raitakari O, Kartiosuo
N, Pahkala K, et al. Lipoprotein(a) in youth and prediction of major
cardiovascular outcomes in adulthood. Circulation. 2023;147(1):23-31.  

 * Contact Us
 * Interest-Based Ads
 * Sitemap
 * Non-US Residents

Novartis Pharmaceuticals Corporation

Use of website is governed by the Terms of Use ↗ and Privacy Policy ↗. 


Copyright © 2023 Novartis Pharmaceuticals Corporation ↗. All rights reserved.

08/23     283430

Back to top



YOU ARE ABOUT TO LEAVE UNCOVERLPA.COM

You are about to leave a Novartis site and continue to an external website
independently operated and not managed by Novartis Pharmaceuticals Corporation.
CONTINUE TO EXTERNAL SITE

YOU ARE ABOUT TO LEAVE UNCOVERLPA.COM

You are now being directed to another Novartis website.
CONTINUE TO EXTERNAL SITE